Tag: PHA MTC HEA

Navamedic ASA – Minutes of Extraordinary General Meeting

OSLO, Norway, July 14, 2025 /PRNewswire/ -- The announced Extraordinary General Meeting of Navamedic ASA was held today at 13.00 CET. All items on the...

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPHA MTC HEA

Action Art Fest Debuts in Napa’s Rail Arts District on August 24th

HashKey OTC Global Posts Robust Growth in Revenue and Transaction Volume

IPC Shopping Centre Introduces a New Retail and Lifestyle Experience through Lagom Life – A Balanced Way to Shop, Eat, and Connect

Tag: PHA MTC HEA

Navamedic ASA – Minutes of Extraordinary General Meeting

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us